



Results

Most isolates were from bloodstream infections ($n=2,483$), followed by urinary tract infections ($n=1,851$) and patients hospitalized with pneumonia ($n=1,480$).

The most common species was *Escherichia coli* ($n=2,895$) followed by *Klebsiella pneumoniae* ($n=1,279$).

Against CRE, cefiderocol had higher susceptibility (96.5/84.3%, CLSI/EUCAST) than the BL/BLI combinations (Table 1).

Cefiderocol maintained activity against isolates resistant to the BL/BLI combinations, including ceftazidime-avibactam-resistant isolates (Table 1, Figure 2).

Conclusions

Cefiderocol had broad activity against European Enterobacterales isolates, including those resistant to approved BL/BLI combinations.

These data suggest that cefiderocol is an important option for the treatment of serious infections caused by CRE and BL/BLI-resistant Gram-negative pathogens that have limited treatment options.

Acknowledgements

This study was sponsored by Shionogi & Co. LTD.

Contact

Dee Shortridge, PhD
Dee-Shortridge@jmilabs.com

